4-基南通过改变肠道微生物群和胆酸代谢来加剧肥胖症
Guoqiang Qin1,2, Zhen Xu2, Chao Yuan2
1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Nature communications
|March 14, 2026
概括
通过破坏肠道细菌,暴露于环境毒素4-基氨 (4-OHPhe) 会增加肥胖的风险. 这导致有益化合物减少,损害新陈代谢,并在雄性小鼠中促进肥胖.
科学领域:
- 环境科学 环境科学
- 微生物学 微生物学
- 代谢研究研究 代谢研究
背景情况:
- 增加的4-基南 (4-OHPhe) 暴露与肥胖有关.
- 驱动这种关联的精确机制尚未完全理解.
研究的目的:
- 阐明将4-OHPhe暴露与肥胖联系在一起的致病机制.
- 研究肠道微生物群在调解这种效果中的作用.
主要方法:
- 使用了夏普利添加式扩展 (SHAP) 和后勤回归.
- 在Bacteroides uniformis (B. uniformis) 中分析了基因表达的变化.
- 评估了对雄性小鼠反应性氧物种 (ROS) 水平,胆酸生产和宿主代谢的影响.
主要成果:
- 4-OHPhe降低了B. uniformis中氨酸减少酶 (hcp) 基因的下调,抑制了ROS的去除并减少了B. uniformis的丰度.
- 减少B. uniformis导致氧化胆酸 (HDCA) 生产减少,影响法纳索伊德X受体 (FXR) - 胺路径.
- 这种级联导致下调的白色脂肪组织 (WAT) 热生成基因和肥胖,这种效应被B. uniformis或HDCA的管理逆转.
结论:
- 4-OHPhe通过破坏肠道微生物群的组成和功能而加剧肥胖.
- 建立了环境毒素,肠道失调和宿主代谢功能障碍之间的机械联系.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
262
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
343
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Drug Dosing: Obese Patients
325
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Overview of Lipid Metabolism
6.4K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.4K


